No data to show
XSTO
VIMIAN
Market cap2.01bUSD
Apr 14, Last price
37.90SEK
1D
3.33%
1Q
-1.04%
IPO
-56.93%
Name
Vimian Group AB
Chart & Performance
P/E
95.18
P/S
4.70
EPS
0.04
Div Yield, %
—
Shrs. gr., 5y
6.08%
Rev. gr., 5y
72.51%
Revenues
375m
+12.98%
Net income
19m
+88.01%
CFO
58m
P
Earnings
Apr 30, 2025
Profile
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 374,800 12.98% | 331,730 17.92% | 281,308 62.28% | |||||
Cost of revenue | 116,500 | 107,975 | 152,597 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 258,300 | 223,755 | 128,711 | |||||
NOPBT Margin | 68.92% | 67.45% | 45.75% | |||||
Operating Taxes | 9,500 | 8,963 | 8,122 | |||||
Tax Rate | 3.68% | 4.01% | 6.31% | |||||
NOPAT | 248,800 | 214,792 | 120,589 | |||||
Net income | 18,500 88.01% | 9,840 -236.70% | (7,198) -209.29% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 142,700 | 443 | 139,627 | |||||
BB yield | -0.69% | 0.00% | -1.27% | |||||
| Debt | ||||||||
Debt current | 4,700 | 3,490 | 4,816 | |||||
Long-term debt | 246,600 | 322,043 | 229,986 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 35,100 | 61,770 | 35,259 | |||||
Net debt | 186,500 | 230,464 | 180,927 | |||||
| Cash flow | ||||||||
Cash from operating activities | 58,100 | (28,576) | 25,313 | |||||
CAPEX | (6,300) | (7,926) | (10,308) | |||||
Cash from investing activities | (76,000) | (77,677) | (188,533) | |||||
Cash from financing activities | 44,800 | 100,545 | 150,229 | |||||
FCF | 237,040 | 158,956 | 122,749 | |||||
| Balance | ||||||||
Cash | 64,800 | 37,500 | 42,194 | |||||
Long term investments | 57,569 | 11,681 | ||||||
Excess cash | 46,060 | 78,482 | 39,810 | |||||
Stockholders' equity | 88,200 | 58,833 | 52,972 | |||||
Invested Capital | 929,140 | 843,449 | 689,724 | |||||
ROIC | 28.07% | 28.02% | 20.20% | |||||
ROCE | 25.71% | 24.80% | 17.07% | |||||
| EV | ||||||||
Common stock shares outstanding | 522,718 | 453,497 | 403,114 | |||||
Price | 39.80 34.46% | 29.60 8.74% | 27.22 -65.70% | |||||
Market cap | 20,804,176 54.98% | 13,423,518 22.33% | 10,972,766 -60.49% | |||||
EV | 20,997,276 | 13,654,320 | 11,157,837 | |||||
EBITDA | 258,300 | 255,787 | 155,938 | |||||
EV/EBITDA | 81.29 | 53.38 | 71.55 | |||||
Interest | 19,255 | 11,052 | ||||||
Interest/NOPBT | 8.61% | 8.59% | ||||||